Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
Baseline lipoprotein(a) was inversely associated with risk of NOD. Alirocumab-induced reductions of lipoprotein(a) and LDL-C were associated with increased and decreased risk of NOD, respectively, without net effect on NOD. Ongoing trials will determine the impact of larger and longer lipoprotein(a) reductions on NOD.
Authors
- Philippe Gabríel Steg (ORCID: https://orcid.org/0000-0001-6896-2941)
- J. Wouter Jukema (ORCID: https://orcid.org/0000-0002-3246-8359)
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- Christa M. Cobbaert (ORCID: https://orcid.org/0000-0003-3565-1404)
- Geneviève Garon (ORCID: https://orcid.org/0009-0001-0486-6325)
- Shaun G. Goodman (ORCID: https://orcid.org/0000-0001-8068-2440)
- Vera Bittner (ORCID: https://orcid.org/0000-0001-9456-850X)
- Esther Reijnders (ORCID: https://orcid.org/0000-0003-3520-5869)
- Harvey D. White (ORCID: https://orcid.org/0000-0001-7712-6750)
- Gregory G. Schwartz (ORCID: https://orcid.org/0000-0003-2954-0695)
- Michael Szarek (ORCID: https://orcid.org/0000-0002-0046-0264)
- Markus Schwertfeger
- Sergio Fazio (ORCID: https://orcid.org/0000-0002-8145-8034)
- Robert A. Harrington
Institutions
- Roche (Switzerland) (CH)
- St. Michael's Hospital (CA)
- State University of New York (US)
- University of Auckland (NZ)
- University of Alberta (CA)
- Inserm (FR)
- SUNY Downstate Health Sciences University (US)
- University of Toronto (CA)
- Institut Universitaire de France (FR)
- Regeneron (United States) (US)
- Université Paris Cité (FR)
- Cornell University (US)
- Leiden University Medical Center (NL)
- University of Alabama at Birmingham (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- Sanofi (Canada) (CA)
- Netherlands Heart Institute (NL)
- Canadian VIGOUR Centre (CA)
- Hôpital Bichat-Claude-Bernard (FR)
- University of Colorado Denver (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-02-06
- DOI
- https://doi.org/10.2337/dc24-2110
- Citations
- 9
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 18.06
Funders
- U.S. Department of Veterans Affairs
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Heart and Stroke Foundation of Canada
- Brigham and Women's Hospital
- Patient-Centered Outcomes Research Institute
- Alnylam Pharmaceuticals
- Edwards Lifesciences
- Cleveland Clinic
- CSL Behring
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Ironwood Pharmaceuticals, Incorporated
- Amarin Corporation
- Cytokinetics
- Medicines Company
- MyoKardia
- Belvoir Media Group
- Moderna
- York University
- University of Oxford
- University of Toronto
- Eisai
- Novo Nordisk
- Assistance publique-Hôpitaux de Paris
- Servier
- Idorsia Pharmaceuticals
- HLS Therapeutics
- Sanofi Australia
- Silence Therapeutics
- Esperion Therapeutics
- National Institutes of Health
- Genentech
- St. Jude Medical
- American Regent
- Roche Diagnostics
- Netherlands Heart Institute
- Duke Clinical Research Institute
- Daiichi Sankyo Europe